<p>Monte Rosa Therapeutics, Inc.（納斯達克代碼：GLUE - 獲取免費報告）週一股價上漲 10.8%，此前富國銀行將其目標股價從 10.00 美元上調至 13.00 美元。富國銀行目前對該股票維持平等權重評級。Monte Rosa Therapeutics 的股價最高曾達到 13.59 美元，最後交易價為 13.64 美元。在交易過程中，約有 448,769 股易手，較 836,201 股的日均成交量下降了 46%。該股票此前收於 12.31 美元。</p>
<p>另外，Weiss Ratings 在 10 月 31 日星期五的研究報告中重申了對 Monte Rosa Therapeutics 股票的 “賣出（d+）” 評級。兩位投資分析師給予該股票買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，Monte Rosa Therapeutics 目前的平均評級為 “持有”，平均目標股價為 16.33 美元。</p>
<p><strong>查看我們關於 GLUE 的最新研究報告</strong></p>
<h2>對 Monte Rosa Therapeutics 的對沖基金看法</h2>
<p>幾家對沖基金和其他機構投資者最近調整了對 GLUE 的持倉。Pallas Capital Advisors LLC 在第二季度購買了 Monte Rosa Therapeutics 的新股份，價值約 59,000 美元。American Century Companies Inc.在第一季度將其在 Monte Rosa Therapeutics 的持股增加了 30.7%。American Century Companies Inc.目前擁有 100,406 股該公司的股票，價值 466,000 美元，此前在此期間又收購了 23,556 股。CWM LLC 在第二季度將其在 Monte Rosa Therapeutics 的股份增加了 664.3%。CWM LLC 目前擁有 28,326 股該公司的股票，價值 128,000 美元，此前在此期間又購買了 24,620 股。Nuveen LLC 在第一季度購買了 Monte Rosa Therapeutics 的新股份，價值約 546,000 美元。最後，Brighton Jones LLC 在第二季度獲得了 Monte Rosa Therapeutics 的新股份，價值 48,000 美元。79.96% 的股票由機構投資者持有。</p>
<h2>Monte Rosa Therapeutics 股票表現</h2>
<p>該股票市值為 8.9052 億美元，市盈率為 42.67，貝塔值為 1.61。該股票的 50 日移動平均線為 8.43 美元，200 日移動平均線為 6.03 美元。</p>
<p>Monte Rosa Therapeutics（納斯達克代碼：GLUE - 獲取免費報告）最後一次公佈財報是在 11 月 6 日星期四。該公司報告本季度每股收益（EPS）為-0.33 美元，超出分析師一致預期的-0.39 美元，超出幅度為 0.06 美元。該季度的營業收入為 1277 萬美元，而分析師預期為 737 萬美元。Monte Rosa Therapeutics 的淨利潤率為 11.54%，股本回報率為 8.20%。分析師預測 Monte Rosa Therapeutics, Inc.本年度將發佈-1.49 的每股收益。</p>
<h2>Monte Rosa Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Monte Rosa Therapeutics, Inc.是一家臨牀階段的生物技術公司，專注於開發新型小分子精準藥物，利用人體自然機制選擇性降解具有治療相關性的蛋白質。該公司開發了 MRT-2359，這是一種口服生物可用的分子膠降解劑，針對翻譯終止因子蛋白 GSPT1，用於治療 MYC 驅動的腫瘤；MRT-6160 用於治療系統性和中樞神經系統自身免疫疾病；以及 MRT-8102 用於治療 IL-1?/NLRP3 驅動的炎症性疾病。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Monte Rosa Therapeutics</li>
<li>每月分紅股票的利與弊</li>
<li>盈利勝利與股票下跌：D-Wave 發生了什麼？</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>在市場回調時顯示相對強勢的三隻股票</li>
<li>什麼是分紅之王？</li>
<li>如果市場持續下滑，值得關注的五隻防禦性消費股</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Monte Rosa Therapeutics 嗎？</h2>
<p>在您考慮投資 Monte Rosa Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Monte Rosa Therapeutics 並不在名單上。</p>
<p>雖然 Monte Rosa Therapeutics 目前在分析師中獲得持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

GLUE

<p>蒙特羅莎治療公司（NASDAQ:GLUE）股價上漲 10.8%，因富國銀行將其目標價從 10.00 美元上調至 13.00 美元，並維持 “持平” 評級。該股最高交易價達到 13.59 美元，最後交易價為 13.64 美元。儘管如此，Weiss Ratings 重申了 “賣出（d+）” 評級。機構投資者持有該股 79.96% 的股份。公司報告每股收益為（0.33 美元），超出預期，季度收入為 1277 萬美元。分析師預測當前年度每股收益為-1.49 美元</p>

<p>Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) shares rose 10.8% on Monday after Wells Fargo &amp; Company raised their price target on the stock from $10.00 to $13.00. Wells Fargo &amp; Company currently has an equal weight rating on the stock. Monte Rosa Therapeutics traded as high as $13.59 and last traded at $13.64. Approximately 448,769 shares changed hands during trading, a decline of 46% from the average daily volume of 836,201 shares. The stock had previously closed at $12.31.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics, Inc.（納斯達克代碼：GLUE - 獲取免費報告）週一股價上漲 10.8%，此前富國銀行將其目標股價從 10.00 美元上調至 13.00 美元。富國銀行目前對該股票維持平等權重評級。Monte Rosa Therapeutics 的股價最高曾達到 13.59 美元，最後交易價為 13.64 美元。在交易過程中，約有 448,769 股易手，較 836,201 股的日均成交量下降了 46%。該股票此前收於 12.31 美元。</p>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of Monte Rosa Therapeutics in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Monte Rosa Therapeutics presently has an average rating of &#34;Hold&#34; and an average price target of $16.33.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 31 日星期五的研究報告中重申了對 Monte Rosa Therapeutics 股票的 “賣出（d+）” 評級。兩位投資分析師給予該股票買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，Monte Rosa Therapeutics 目前的平均評級為 “持有”，平均目標股價為 16.33 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on GLUE</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 GLUE 的最新研究報告</strong></p>
</div><h2>Hedge Funds Weigh In On Monte Rosa Therapeutics</h2>
<div class="lb-trans"><h2>對 Monte Rosa Therapeutics 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of GLUE. Pallas Capital Advisors LLC purchased a new position in shares of Monte Rosa Therapeutics during the second quarter worth approximately $59,000. American Century Companies Inc. grew its holdings in Monte Rosa Therapeutics by 30.7% during the first quarter. American Century Companies Inc. now owns 100,406 shares of the company's stock worth $466,000 after acquiring an additional 23,556 shares during the period. CWM LLC grew its stake in shares of Monte Rosa Therapeutics by 664.3% during the 2nd quarter. CWM LLC now owns 28,326 shares of the company's stock worth $128,000 after purchasing an additional 24,620 shares during the period. Nuveen LLC purchased a new position in Monte Rosa Therapeutics during the first quarter worth approximately $546,000. Finally, Brighton Jones LLC acquired a new position in Monte Rosa Therapeutics during the second quarter worth $48,000. 79.96% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近調整了對 GLUE 的持倉。Pallas Capital Advisors LLC 在第二季度購買了 Monte Rosa Therapeutics 的新股份，價值約 59,000 美元。American Century Companies Inc.在第一季度將其在 Monte Rosa Therapeutics 的持股增加了 30.7%。American Century Companies Inc.目前擁有 100,406 股該公司的股票，價值 466,000 美元，此前在此期間又收購了 23,556 股。CWM LLC 在第二季度將其在 Monte Rosa Therapeutics 的股份增加了 664.3%。CWM LLC 目前擁有 28,326 股該公司的股票，價值 128,000 美元，此前在此期間又購買了 24,620 股。Nuveen LLC 在第一季度購買了 Monte Rosa Therapeutics 的新股份，價值約 546,000 美元。最後，Brighton Jones LLC 在第二季度獲得了 Monte Rosa Therapeutics 的新股份，價值 48,000 美元。79.96% 的股票由機構投資者持有。</p>
</div><h2>Monte Rosa Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Monte Rosa Therapeutics 股票表現</h2>
</div><p>The stock has a market cap of $890.52 million, a PE ratio of 42.67 and a beta of 1.61. The stock's 50-day moving average is $8.43 and its two-hundred day moving average is $6.03.</p>
<div class="lb-trans"><p>該股票市值為 8.9052 億美元，市盈率為 42.67，貝塔值為 1.61。該股票的 50 日移動平均線為 8.43 美元，200 日移動平均線為 6.03 美元。</p>
</div><p>Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.06. The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $7.37 million. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.20%. Analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics（納斯達克代碼：GLUE - 獲取免費報告）最後一次公佈財報是在 11 月 6 日星期四。該公司報告本季度每股收益（EPS）為-0.33 美元，超出分析師一致預期的-0.39 美元，超出幅度為 0.06 美元。該季度的營業收入為 1277 萬美元，而分析師預期為 737 萬美元。Monte Rosa Therapeutics 的淨利潤率為 11.54%，股本回報率為 8.20%。分析師預測 Monte Rosa Therapeutics, Inc.本年度將發佈-1.49 的每股收益。</p>
</div><h2>Monte Rosa Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Monte Rosa Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics, Inc.是一家臨牀階段的生物技術公司，專注於開發新型小分子精準藥物，利用人體自然機制選擇性降解具有治療相關性的蛋白質。該公司開發了 MRT-2359，這是一種口服生物可用的分子膠降解劑，針對翻譯終止因子蛋白 GSPT1，用於治療 MYC 驅動的腫瘤；MRT-6160 用於治療系統性和中樞神經系統自身免疫疾病；以及 MRT-8102 用於治療 IL-1?/NLRP3 驅動的炎症性疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Monte Rosa Therapeutics</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>An Earnings Win With a Stock Slump: What's Happening With D-Wave?</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Stocks Showing Relative Strength as Markets Pull Back</li>
<li>What is a Dividend King?</li>
<li>5 Defensive Consumer Plays to Watch If Markets Keep Slipping</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Monte Rosa Therapeutics</li>
<li>每月分紅股票的利與弊</li>
<li>盈利勝利與股票下跌：D-Wave 發生了什麼？</li>
<li>房地產投資信託是否值得在您的投資組合中佔有一席之地？</li>
<li>在市場回調時顯示相對強勢的三隻股票</li>
<li>什麼是分紅之王？</li>
<li>如果市場持續下滑，值得關注的五隻防禦性消費股</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Monte Rosa Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Monte Rosa Therapeutics 嗎？</h2>
</div><p>Before you consider Monte Rosa Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮投資 Monte Rosa Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Monte Rosa Therapeutics 並不在名單上。</p>
</div><p>While Monte Rosa Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Monte Rosa Therapeutics 目前在分析師中獲得持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Monte Rosa Therapeutics（納斯達克股票代碼：GLUE）在分析師上調評級後股價上漲 10.8%